A groundbreaking study published in the prestigious journal Nature reveals a crucial mechanism by which the most common oncogenic fusion protein found in pediatric ependymoma—the ZFTA-RELA fusion—drives tumor development. Leading researchers from St. Jude Children’s Research Hospital and Baylor College of Medicine have uncovered how this fusion protein hijacks specific regulatory sequences within the genome to maintain immature brain cells in an arrested developmental state. This discovery not only advances our understanding of ependymoma tumor biology but also opens promising avenues for targeted therapies that could disrupt this pathological state and improve patient outcomes.
Ependymomas are among the most frequently diagnosed brain tumors in children, notorious for their resistance to conventional chemotherapy and the high likelihood of disease relapse. Prior to this study, the molecular mechanisms through which ZFTA-RELA fusions contribute to tumor formation remained elusive. Unlike typical oncogenic proteins that significantly alter chromatin accessibility to activate growth-promoting gene programs, ZFTA-RELA operates differently. The research team observed that chromatin accessibility patterns were largely preserved, suggesting that the fusion protein exploits pre-existing developmental regulatory landscapes rather than establishing new ones.
Stephen Mack, PhD, co-corresponding author and developmental neurobiologist at St. Jude, elaborated: “Our findings defy conventional expectations surrounding oncogenic fusion proteins. The ZFTA-RELA fusion does not engender widespread chromatin remodeling. Instead, it occupies regulatory regions already configured during normal brain development, effectively locking cells in a state akin to developmental limbo.” This unique mode of action points to the fusion protein’s ability to maintain the activation of gene programs that should normally be transient during normal neural maturation.
Central to this mechanism is the mimicry of PLAG/L family proteins by the ZFTA-RELA fusion. PLAG/L proteins are key developmental regulators, which bind discrete DNA sequences to activate gene expression programs essential for early cell differentiation. Normally, these PLAG/L-mediated programs close once the cells reach a mature state. The ZFTA-RELA fusion, however, binds to the same DNA motifs and perpetuates the activity of these early developmental programs, effectively preventing the normal maturation cascade. This pathological persistence of immature gene programs underlies tumor proliferation and resistance to therapy.
Alisha Kardian, a graduate student involved in the study, emphasized the therapeutic implications: “By elucidating how normal cells attenuate PLAG/L chromatin accessibility, we can begin exploring strategies to counteract the oncogenic mimicry exerted by ZFTA-RELA. Targeting this interaction holds promise for novel interventions that push tumor cells out of their arrested state.” This insight suggests that directing therapy towards forcing maturation of tumor cells could bypass resistance mechanisms inherent to immature, proliferative cell states.
Additionally, the investigation uncovered remarkable details regarding tumor cell heterogeneity and clonal dominance within ependymomas harboring ZFTA-RELA fusions. Despite the abnormal activation of multiple developmental pathways, the tumor population stems predominantly from a limited number of ancestral “winner” cells. These dominant clones possess the capability to toggle between diverse developmental gene programs, illustrating the fusion protein’s role in orchestrating a flexible transcriptional landscape conducive to tumor growth.
Dr. Mack pointed out a critical threshold phenomenon: “Our data suggest the existence of a ‘sweet spot’ for ZFTA-RELA expression that drives oncogenic activity. Suboptimal levels of fusion protein fail to sustain proliferative programs, whereas excessive expression proves cytotoxic. This nuance underlines why residual tumor cells—even in minimal numbers—pose a high risk for relapse post therapy.” Such findings spotlight the challenges in completely eradicating tumor clones and stress the need for highly effective, sustained treatments.
Current treatment paradigms for pediatric ependymoma rely heavily on surgical resection and radiotherapy, with chemotherapy often proving ineffective. The revelation of this developmental roadblock imposed by ZFTA-RELA spotlights a critical avenue for innovation. By aiming to pharmacologically or genetically push cells beyond their arrested immature state, therapies could overcome intrinsic resistance and reduce relapse rates, bringing new hope to patients and families affected by this devastating disease.
Kelsey Bertrand, MD, co-corresponding author and oncologist at St. Jude, remarked on the clinical significance: “Ependymomas’ resilience against standard chemotherapy has long impeded successful long-term treatment. This foundational understanding of the ZFTA-RELA fusion’s role in maintaining cell immaturity provides a much-needed direction for future therapeutic development, potentially overcoming these barriers.” The collaborative effort underscores the power of integrative research bridging developmental biology with oncology.
The study’s cohort was a multidisciplinary consortium spanning multiple institutions, including St. Jude Children’s Research Hospital, Baylor College of Medicine, University of Bath, UT Southwestern, Dana-Farber Cancer Institute, University of California San Francisco, and others. Their combined expertise in genomics, neurobiology, cancer biology, and clinical oncology enabled the comprehensive dissection of this complex fusion protein’s function.
Funding support spanned numerous prestigious agencies, including the National Cancer Institute, Department of Defense, National Institutes of Health, National Brain Tumor Society, Alex’s Lemonade Stand Foundation, and many philanthropic organizations supporting pediatric cancer research. This extensive backing reflects the critical importance and promise of the study’s discoveries in addressing childhood brain tumors.
By elucidating the fundamentally novel approach by which the ZFTA-RELA fusion protein sustains pediatric ependymoma cells in a non-mature state, this research breaks new ground. It challenges established models of oncogenic transformation and compels the field to consider developmentally focused therapies that shift tumor cell states as a viable and innovative therapeutic strategy.
Subject of Research: Pediatric ependymoma and oncogenic fusion proteins
Article Title: Fusion oncoprotein ZFTA-RELA locks pediatric ependymoma cells in developmental limbo
News Publication Date: March 25, 2026
Web References:
https://www.stjude.org
https://dx.doi.org/10.1038/s41586-026-10270-8
Image Credits: St. Jude Children’s Research Hospital
Keywords: Pediatric brain tumors, ependymoma, ZFTA-RELA fusion, oncogenic fusion protein, chromatin accessibility, developmental biology, tumor cell heterogeneity, pediatric oncology, fusion oncoprotein mechanisms, cellular differentiation blockade, therapeutic resistance
